Clinical trial · Interventional
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer
NCT04747717CI-TRIAL-00050021unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study was designed to assess the safety and efficacy of neoadjuvant therapy with mitomycin C plus cisplatin (MP) in BRCA1-mutated ovarian cancer versus standard regimen (paclitaxel plus carboplatin (TP)).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemotherapy/surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Mitomycin C and cisplatin regimen
- description
- mitomycin C at 10 mg/m2 and cisplatin at 100 mg/m2
- interventionNames
- Procedure: chemotherapy/surgery
- type
- ACTIVE_COMPARATOR
- label
- Paclitaxel and carboplatin regimen
- description
- paclitaxel at 175 mg/m2 and carboplatin AUC5-6
- interventionNames
- Procedure: chemotherapy/surgery
Primary outcomes (3)
- measure
- Response rate
- timeFrame
- 4 months after FPFV
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed epithelial ovarian carcinoma or fallopian tubes carcinoma * FIGO stage IIB, IIC, III, or IV disease * BRCA1/BRCA2 germline mutation Exclusion Criteria: * WHO performance status \>3 * FIGO early stage * wt BRCA status * cytological verification
References
Publications (1)
pubmedProvenance
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
Tatiana V Gorodnova, Anna P Sokolenko, Khristina B Kotiv et al. · Int J Cancer · Sep 25, 2026 · PMID 42788407 pubmed